Retatrutide
Also known as: LY3437943, Triple Hormone Receptor Agonist, Reta
Investigational triple agonist (GIP, GLP-1, and glucagon) for weight loss and metabolic health, currently in Phase 3 trials. Weekly SubQ. Not yet FDA-approved.
Pharmacokinetics
- Half-life
- 6 days
- Time to peak
- 48 hours
- Bioavailability
- 70%
- Onset
- 1 hours
- Dosing interval
- Weekly (7d)
Administration
- Primary routes
- SubQ
- Category
- GLP-1 Receptor Agonists
Safety Flags
- High immunogenicity
- Contraindicated in cancer history
- Contraindicated in MEN2 / MTC
Storage
- · Requires refrigeration (2–8°C)
- · Temperature sensitive — minimise room-temp exposure
Used in 5 outcome protocols
- Fat Loss (Lipolysis)Primary
Accelerate fat metabolism and lipolysis without affecting growth hormone levels
Safe default: 6mg · weekly · SubQ
- Blood Sugar
Regulate blood glucose levels and improve glycemic control
Safe default: 6mg · weekly · SubQ
- Appetite SuppressionPrimary
Reduce appetite and support weight management goals
Safe default: 6mg · weekly · SubQ
- Insulin Sensitivity
Improve cellular response to insulin and metabolic health
Safe default: 6mg · weekly · SubQ
- Cardio Health
Support cardiovascular function and vascular health
Safe default: 6mg · weekly · SubQ
Simulate Retatrutide
Pinned.life runs a 1-compartment Bateman pharmacokinetic simulation against 38 peptides in real time. Build a stack, see serum-level curves, get warned about peak overlaps and drug-peptide interactions.